THE U.S. Food & Drug Administration announced April 1 that it has received a letter of commitment from Zoetis that the company will suspend sales of Histostat (nitarsone) by the fall and formally request that FDA withdraw its approval by the end of 2015.
Nitarsone is the only arsenic-based animal drug that is currently approved for use in food animals, including for the prevention of blackhead disease (his
All access premium subscription
This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.
Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)
Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit Feedstuffs.com and click on Subscribe at the top of the page for more information.
SUBSCRIBE NOW https://circulation.feedstuffs.com/Publications.aspx
TO RENEW YOUR SUBSCRIPTION https://circulation.feedstuffs.com/SubscriptionOffers.aspx